Holen Sie sich die Stockscreener-App
11.67
5.43%
-0.67
Handel nachbörslich:
11.82
0.15
+1.29%
Schlusskurs vom Vortag:
$12.34
Offen:
$12.14
24-Stunden-Volumen:
21,850
Relative Volume:
0.41
Marktkapitalisierung:
$10.70M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.93M
KGV:
-0.0438
EPS:
-266.137
Netto-Cashflow:
$-15.87M
1W Leistung:
+33.52%
1M Leistung:
+67.67%
6M Leistung:
-0.60%
1J Leistung:
-93.90%
1-Tages-Spanne:
$11.62
$12.34
1-Wochen-Bereich:
$8.66
$12.60
52-Wochen-Spanne:
$6.0829
$468.44
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Firmenname
Transcode Therapeutics Inc
Sektor
Branche
Telefon
857-301-6857
Adresse
6 LIBERTY SQUARE, BOSTON
Vergleichen Sie RNAZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
11.67 | 11.32M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Transcode Therapeutics Inc Aktie (RNAZ) Neueste Nachrichten
Earnings Recap: Is TransCode Therapeutics Inc a good stock for dollar cost averagingPortfolio Performance Summary & Weekly Breakout Watchlists - baoquankhu1.vn
Market Recap: Is TransCode Therapeutics Inc a good stock for dollar cost averagingJuly 2025 PostEarnings & Stepwise Trade Signal Guides - baoquankhu1.vn
Short Squeeze: Should I hold or sell TransCode Therapeutics Inc nowJuly 2025 Recap & Real-Time Volume Spike Alerts - baoquankhu1.vn
Market Catalysts: Is TransCode Therapeutics Inc a speculative investmentQuarterly Portfolio Report & Fast Gain Swing Alerts - baoquankhu1.vn
Entry Recap: How does OLPX compare to its peersWeekly Profit Summary & Growth Focused Stock Pick Reports - baoquankhu1.vn
Is TransCode Therapeutics Inc. stock in correction or buying zone2025 Volume Leaders & High Yield Equity Trading Tips - bollywoodhelpline.com
Options Flow: Does TransCode Therapeutics Inc have pricing powerJuly 2025 Earnings & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Fundamentals Check: Is TransCode Therapeutics Inc attractive for institutional investors2025 Trade Ideas & AI Based Buy and Sell Signals - baoquankhu1.vn
Bull Bear: What are analysts price targets for TransCode Therapeutics IncJuly 2025 Pullbacks & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Market Recap: What are analysts price targets for TransCode Therapeutics IncJuly 2025 Technicals & Reliable Price Breakout Alerts - baoquankhu1.vn
Will TransCode Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Gainers & AI Powered Market Entry Strategies - Улправда
MSN Money - MSN
Is TransCode Therapeutics Inc. stock attractive for income investorsBreathability and Upper Notes & HOKA model picks for your routine - ulpravda.ru
Will TransCode Therapeutics Inc. stock split again soonJuly 2025 Closing Moves & Weekly High Return Stock Opportunities - Улправда
Why retail investors pile into TransCode Therapeutics Inc. stockWeekly Trade Review & Reliable Entry Point Alerts - Улправда
TransCode Therapeutics, Inc.Common Stock (NQ: RNAZ - FinancialContent
Can TransCode Therapeutics Inc. stock double in next 5 years2025 Volatility Report & Risk Managed Trade Strategies - Улправда
TransCode’s glioblastoma therapy shows promise in preclinical study By Investing.com - Investing.com Nigeria
(RNAZ) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
How TransCode Therapeutics Inc. stock benefits from tech adoption2026 world cup usa national team quarterfinals midfield engines counter attacking knockout prediction tactical review - ulpravda.ru
TransCode Therapeutics Publishes Preclinical Data Supporting TTX-MC138 for Glioblastoma Treatment - citybuzz -
Transcode Therapeutics Ttx-Mc138 phase 2a clinical trial expected in first half of 2026 - marketscreener.com
Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026 - TradingView — Track All Markets
TransCode Therapeutics reports promising preclinical glioblastoma results - TipRanks
TransCode Therapeutics stock soars after promising glioblastoma study By Investing.com - Investing.com Canada
TransCode Therapeutics Publishes Preclinical Data on TTX-MC138 for Glioblastoma - TradingView — Track All Markets
TransCode’s glioblastoma therapy shows promise in preclinical study - Investing.com
Experimental RNA therapy extends survival in brain cancer animal tests - Stock Titan
TransCode reports positive phase 1 trial progress for cancer therapy - MSN
Precision Trading with Transcode Therapeutics Inc. (RNAZ) Risk Zones - Stock Traders Daily
TransCode Therapeutics appoints Jack E. Stover to board of directors By Investing.com - Investing.com Nigeria
TransCode Therapeutics Appoints Industry Veteran Jack E. Stover to Board of Directors - citybuzz -
TransCode Therapeutics Strengthens Board with Veteran Financial Expert - TipRanks
Transcode Therapeutics Appoints Jack Stover to Board of Directors - TradingView — Track All Markets
TransCode Therapeutics appoints Jack E. Stover to board of directors - Investing.com India
TransCode Therapeutics expands leadership with appointment of Jack E. Stover to board of directors - marketscreener.com
Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors - TradingView — Track All Markets
Life sciences leader behind a $900M pharma sale joins cancer firm - Stock Titan
Why TransCode Therapeutics Inc. stock is favored by top institutionsQuarterly Market Summary & Real-Time Buy Zone Alerts - Улправда
TransCode Therapeutics Earnings Notes - Trefis
TransCode Therapeutics (NASDAQ:RNAZ) Shares Down 4.6% – Here’s What Happened - Defense World
TransCode Therapeutics Inc Stock Analysis and ForecastMACD Histogram Signals & Superior Trading Ideas - earlytimes.in
TransCode and Quantum Leap to test cancer therapy in phase 2a trial - Investing.com Australia
TransCode Therapeutics and Quantum Leap Collaborate on Colorectal Cancer Trial Targeting Metastatic Disease - citybuzz
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
TransCode and Quantum Leap to test cancer therapy in phase 2a trial By Investing.com - Investing.com South Africa
TransCode Therapeutics and Quantum Leap Healthcare Collaborative launch a phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's phase 1 trial - marketscreener.com
TransCode Therapeutics Announces Phase 2a Trial Collaboration - TradingView — Track All Markets
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial - PR Newswire
Buyout Rumor: Why hedge funds are buying NETSTREIT Corp. stockInsider Selling & Expert Curated Trade Ideas - moha.gov.vn
Critical Comparison: TransCode Therapeutics (NASDAQ:RNAZ) & ReNeuron Group (OTCMKTS:RNUGF) - Defense World
Finanzdaten der Transcode Therapeutics Inc-Aktie (RNAZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):